Radient Pharmaceuticals enters distribution agreement with Grifols USA for DR-70 Onko-Sure

Radient Pharmaceuticals Corporation, through its wholly-owned subsidiary AMDL Diagnostics, Inc. (ADI), has entered into an exclusive 5-year marketing and distribution agreement with Grifols USA, LLC. Radient is a pharmaceutical company, while Grifols USA is a distributor of medical devices. All the companies are based in the US.

ADI is engaged in the research, development, manufacture and international sales of Onko-Sure(TM), an in vitro diagnostic (IVD) cancer test.

Under the terms of the agreement, Grifols USA will market and sell ADI's DR-70 Onko-Sure cancer test for the monitoring of colorectal cancer (CRC) to hospitals, clinical labs, clinics and other healthcare organizations throughout the US.

According to agreement, Grifols USA has the rights to market and distribute ADI's Onko-Sure cancer test specifically for the monitoring of colorectal cancer in the US.

Deal Type    Partnership
Sub-Category Marketing,Sales,Acquisition of Rights,Distribution
Deal Status  Announced: 2009-10-08

Deal Participants

Partner 1 (Company) Radient Pharmaceuticals Corporation (formerly AMDL, Inc.)
Partner 2 (Company) AMDL Diagnostics, Inc.
Partner 3 (Company) Grifols USA, LLC
Partner 4 (Company) Grifols, S.A. (Formerly Probitas Pharma, S.A.)

Related terms: acquisition, cancer, clinical, colorectal cancer, distributor, healthcare, manufacturer, market, marketing, medical, partnership, pharmaceuticals, sales